Silver (XAG) Forecast: Price Prediction Points Higher if Fed Confirms 2026 Rate Cuts

Apple's executive shake-up continues.

2 Things Every GE Vernova Investor Needs to Know

Forget Medtronic, Buy This Healthcare Stock Instead

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Centuri Stock Up 18% This Year: What a New $17 Million Position Signals for Investors

BTDR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bitdeer Technologies Group Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

3 Top Stocks to Buy for 2026

10 Energy Stocks to Buy Right Now

FDG: One Of The Few Outperformers In 2025

3 No-Brainer Growth Stocks to Buy for 2026 With $100 Right Now

EPU: A Mining ETF With A Large-Cap Bank

Evaluating VRT Stock's Actual Performance

Why One Investor Just Doubled Down on Clearwater Analytics Stock with a $45 Million Position

Oracle: Why This Selloff Looks Like An Early Christmas Gift

Apple stock under pressure after major executive departures: what it means for AAPL's AI roadmap

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Lantheus Holdings, Inc. (LNTH)

WPP DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages WPP plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 8 Deadline in Securities Class Action - WPP

3 Incredible Growth Stocks to Buy Now

Down 27%, Should You Buy Adobe Stock Before Dec. 10?

Financial Institutions Is Still Worth Banking On

'Trump accounts,' explained: Who qualifies, how they work and when you can claim

Netflix Stock Up 13%. Why $82.7 Billion $WBD Buy Makes $NFLX A Sell

Better Buy for 2026: ExxonMobil or Chevron?

Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Transcript

Value Fund Cuts nCino Stake After $152 Million Quarter: What Long-Term Investors Should Know

Coinbase starts onboarding users again in India, plans for fiat on-ramp next year

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

American Electric Power: Unmatched Reach Make It A Buy

The Merger Fund Q3 2025 Contributors And Detractors

Brookfield, GIC near binding offer for National Storage, Bloomberg News reports

As Growth Accelerates, Is It Time to Buy CrowdStrike Stock?

Cellnex Telecom Is Now A 'Strong Buy'

Exxon Mobil's 43 Year Dividend Streak Looks Secure Despite Falling Earnings

3 Yield-Producing ETFs with Real Staying Power

'PROJECT TALON': Northrop Grumman reveals new 'autonomous wingman'

1 Vanguard ETF I'm Buying in 2026 and Holding Forever

NDMO: I Generally Get Cautious After Sharp Pops Higher (Rating Downgrade)

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO

Why 10%+ Yields Can Wreck Your Retirement Income

Prediction: Nvidia Stock Is Going to Soar Past $300 in 2026

Kessler Topaz Meltzer & Check, LLP Reminds StubHub Holdings, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit

How to trade Apple stock options

Best Marijuana Stocks to Watch Right Now

Why One Investor Bought $67.5 Million in Array Digital Infrastructure Stock

Core Scientific's Meltdown Over, Accelerating AI Monetization From FY 2026

Why QuantumScape Stock Got Crushed in November

Better ETF: Is VCLT's Focus on Corporate Bonds the Superior Approach to TLT's U.S. Treasuries?

Paloma Dumps 200,000 Lattice Semiconductor LSCC Shares in $9.8 Million Exit

Why I'm Buying This ETF Like There's No Tomorrow, and Never Selling

Anthony Scaramucci on Solana's Unsung Crypto Story, MSTR "Levered" Play

American Airlines requests notices in Spirit bankruptcy proceedings

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

Rio Tinto: Reorganization First, Re-Rating Next

Nayax Considering an Offering of Notes and Warrants in Israel

2 Stocks That Could Soar by 52% and 282%, According to Wall Street

FNDA Is A Good Alternative To Large-Cap ETFs Like VUG

Vaalco Energy: Cash Flow Update

UIVM: Unconvincing Blend Of Value And Momentum

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs

The Cut Countdown

MLTX Deadline: MLTX Investors with Losses in Excess of $100K Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

DEFT UPCOMING DEADLINE: Faruqi & Faruqi Reminds In DeFi Technologies Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 30, 2026 - DEFT

FLY DEADLINE: Faruqi & Faruqi Reminds Firefly Aerospace Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FLY

The Market Is Giving Investors an Unbeatable Opportunity to Buy This Long-Term Artificial Intelligence (AI) Winner (Hint: Not Palantir or Nvidia)

VICI Properties: The Drop I Anticipated Arrived (Rating Upgrade)

STUB DEADLINE: Faruqi & Faruqi Reminds StubHub Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 23, 2026 - STUB

KMX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2026 - KMX

GitLab Shares Plunge. Why It May Be Time to Load Up on the Stock Ahead of the New Year.

FCX DEADLINE: Faruqi & Faruqi Reminds Freeport-McMoran Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FCX

Victoria's Secret: The Brand Is Regaining Momentum

BTDR DEADLINE: Faruqi & Faruqi Reminds Bitdeer Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - BTDR

Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel

AVTR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Avantor

Palantir Crushes 63% Growth While UiPath Celebrates Its First Profit

BAX DEADLINE: Faruqi & Faruqi Reminds Baxter International Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - BAX

Costco Holds Steady While Walmart Bets Big on E-Commerce Transformation

Top Wall Street analysts favor these 3 stocks for their growth potential

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

OWL DEADLINE: Faruqi & Faruqi Reminds Blue Owl Capital Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 2, 2026 - OWL

Victoria's Secret: The Reasons Why The Post-Earnings Rally Is Not Justified

Grocers See Increasing Evidence That Consumers Are Feeling More Strain

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

BST: Technology Options CEF With 7.3% Yield, Growth, No Leverage, But Volatility

US Stormwater Management Market Size Worth USD 15.05 Billion by 2033 | SNS Insider

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Oil-Dri Corporation of America: Upside Hasn't Dried Up Yet

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Silver Price Forecast – ETF Inflows and Supply Deficits Set Stage for $100 Surge in 2026

The Trade Desk Is In War Mode

The Generational Shift I See Now - And My 33 Stocks For What's Coming

ARE INVESTOR LOSSES: Lose Money on Alexandria Real Estate Equities, Inc.? Contact BFA Law before January 26 Securities Class Action Deadline

LRN INVESTOR LOSSES: Lose Money on Stride, Inc.? Contact BFA Law before January 12 Securities Class Action Deadline

MLTX INVESTOR LOSSES: Lose Money on MoonLake Immunotherapeutics? Contact BFA Law before December 15 Securities Class Action Deadline

SNPS INVESTOR LOSSES: Lose Money on Synopsys, Inc.? Contact BFA Law before December 30 Securities Class Action Deadline

JEF INVESTOR LOSSES: Lose Money on Jefferies Financial Group Inc.? Contact BFA Law about its Securities Fraud Investigation

FCX INVESTOR LOSSES: Lose Money on Freeport-McMoRan Inc.? Contact BFA Law before January 12 Securities Class Action Deadline